Comparative Pharmacology
Head-to-head clinical analysis: DORIDEN versus EQUAGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORIDEN versus EQUAGESIC.
DORIDEN vs EQUAGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate-like sedative-hypnotic; acts on GABA-A receptors to enhance inhibitory neurotransmission, causing CNS depression.
Equagesic is a combination of aspirin and meprobamate. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis. Meprobamate potentiates GABA-A receptor activity, producing anxiolytic and sedative effects.
500 mg orally at bedtime, maximum 1 g per day; for sedation, 250 mg 3 times daily after meals.
Adults: 1 tablet (200 mg meprobamate, 25 mg ethoheptazine citrate, 325 mg aspirin) orally 3 or 4 times daily.
None Documented
None Documented
Terminal elimination half-life is 4-10 hours in healthy adults; prolonged in elderly and patients with hepatic impairment, increasing to 12-20 hours.
Meprobamate: 10-12 hours in healthy adults, prolonged in liver disease; Aspirin: low doses 2-3 hours, anti-inflammatory doses 15-30 hours (saturable elimination).
Renal (accounting for approximately 80% of elimination, primarily as glucuronide conjugates and unchanged drug); biliary/fecal (minor, about 10%).
Meprobamate: renal (10% as unchanged drug, 80-90% as hydroxylated metabolites); Aspirin: renal (dose-dependent, 50-80% as salicyluric acid, 10% as unchanged salicylate at acidic pH).
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic